TCDB is operated by the Saier Lab Bioinformatics Group
« See all members of the family


3.A.1.208.2
Hepatic canalicular conjugate exporter, ABCC2. cMRP, MRP2, CMOAT (the Dubin-Johnson Syndrome protein) (transports bilirubin glucuronides; E2 17 β glucuronide, dianionic bile salts such as taurocholate, taurochenodeoxycholate sulfate and taurolithocholate sulfate; reduced glutathione; glutathione conjugates; glucuronides; cysteinyl leukotrienes; arsenic-glutathione complexes and glutathione disulfide; also exports anthracyclines, epipodophyllotosine, Vinca alkaloids, cisplatin, methotrexate, and the protease inhibitor, lopinavir) (Chen and Tiwari, 2011; Krumpochova et al., 2012).  MK-571 is an inhibitor (Zhang et al., 2011).  Sterol sensing residues have been identified (Gál et al. 2015). Catalyzes efflux of ochratoxin A (OTA) (Qi et al. 2017). ABCC2 polymorphism and gender correlate with the high-density lipoprotein/ cholesterol response to simvastatin (Liu et al. 2018). Inhibitors and activators of MRP2 as well as BCPR (ABCG2; TC# 3.A.1.204.2) and P-gp (TC#3.A.1.201.1) have been evaluated (Deng et al. 2020). Drug export by several MDR pumps has been examined using 3D organoids derived from the small intestine (Zhang et al. 2021). The farnesyl protein transferase inhibitor, lonafarnib (SCH66336), is an inhibitor of multidrug resistance proteins 1 and 2, Mrp1 and Mrp2 (Wang and Johnson 2003).

Accession Number:Q92887
Protein Name:MRP2 aka MRP aka cMOAT aka ABCC2 aka cMOAT1 aka cMRP
Length:1545
Molecular Weight:174191.00
Species:Homo sapiens (Human) [9606]
Number of TMSs:16
Location1 / Topology2 / Orientation3: Membrane1 / Multi-pass membrane protein2
Substrate alkaloid, glutathione, methotrexate, taurocholic acid, taurolithocholic acid sulfate, anthracycline, lopinavir, mono(glucosyluronic acid)bilirubin

Cross database links:

RefSeq: NP_000383.1   
Entrez Gene ID: 1244   
Pfam: PF00664    PF00005   
OMIM: 237500  phenotype
601107  gene
KEGG: hsa:1244   

Gene Ontology

GO:0005887 C:integral to plasma membrane
GO:0005524 F:ATP binding
GO:0042626 F:ATPase activity, coupled to transmembrane m...
GO:0008514 F:organic anion transmembrane transporter act...
GO:0055085 P:transmembrane transport

References (14)

[1] “A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation.”  Taniguchi K.et.al.   8797578
[2] “cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats.”  Buechler M.et.al.   8662992
[3] “Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome.”  Tsujii H.et.al.   10464142
[4] “The DNA sequence and comparative analysis of human chromosome 10.”  Deloukas P.et.al.   15164054
[5] “The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).”  The MGC Project Teamet.al.   15489334
[6] “Hepatic secretion of conjugated drugs and endogenous substances.”  Keppler D.et.al.   11076395
[7] “Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity.”  Ito K.et.al.   11500505
[8] “Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.”  Daub H.et.al.   18691976
[9] “A quantitative atlas of mitotic phosphorylation.”  Dephoure N.et.al.   18669648
[10] “Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome.”  Wada M.et.al.   9425227
[11] “Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome.”  Toh S.et.al.   10053008
[12] “Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome.”  Keitel V.et.al.   11093739
[13] “Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome.”  Mor-Cohen R.et.al.   11477083
[14] “Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects.”  Ito S.et.al.   11266082

External Searches:

Analyze:

Predict TMSs (Predict number of transmembrane segments)
Window Size: Angle:  
FASTA formatted sequence
1:	MLEKFCNSTF WNSSFLDSPE ADLPLCFEQT VLVWIPLGFL WLLAPWQLLH VYKSRTKRSS 
61:	TTKLYLAKQV FVGFLLILAA IELALVLTED SGQATVPAVR YTNPSLYLGT WLLVLLIQYS 
121:	RQWCVQKNSW FLSLFWILSI LCGTFQFQTL IRTLLQGDNS NLAYSCLFFI SYGFQILILI 
181:	FSAFSENNES SNNPSSIASF LSSITYSWYD SIILKGYKRP LTLEDVWEVD EEMKTKTLVS 
241:	KFETHMKREL QKARRALQRR QEKSSQQNSG ARLPGLNKNQ SQSQDALVLE DVEKKKKKSG 
301:	TKKDVPKSWL MKALFKTFYM VLLKSFLLKL VNDIFTFVSP QLLKLLISFA SDRDTYLWIG 
361:	YLCAILLFTA ALIQSFCLQC YFQLCFKLGV KVRTAIMASV YKKALTLSNL ARKEYTVGET 
421:	VNLMSVDAQK LMDVTNFMHM LWSSVLQIVL SIFFLWRELG PSVLAGVGVM VLVIPINAIL 
481:	STKSKTIQVK NMKNKDKRLK IMNEILSGIK ILKYFAWEPS FRDQVQNLRK KELKNLLAFS 
541:	QLQCVVIFVF QLTPVLVSVV TFSVYVLVDS NNILDAQKAF TSITLFNILR FPLSMLPMMI 
601:	SSMLQASVST ERLEKYLGGD DLDTSAIRHD CNFDKAMQFS EASFTWEHDS EATVRDVNLD 
661:	IMAGQLVAVI GPVGSGKSSL ISAMLGEMEN VHGHITIKGT TAYVPQQSWI QNGTIKDNIL 
721:	FGTEFNEKRY QQVLEACALL PDLEMLPGGD LAEIGEKGIN LSGGQKQRIS LARATYQNLD 
781:	IYLLDDPLSA VDAHVGKHIF NKVLGPNGLL KGKTRLLVTH SMHFLPQVDE IVVLGNGTIV 
841:	EKGSYSALLA KKGEFAKNLK TFLRHTGPEE EATVHDGSEE EDDDYGLISS VEEIPEDAAS 
901:	ITMRRENSFR RTLSRSSRSN GRHLKSLRNS LKTRNVNSLK EDEELVKGQK LIKKEFIETG 
961:	KVKFSIYLEY LQAIGLFSIF FIILAFVMNS VAFIGSNLWL SAWTSDSKIF NSTDYPASQR 
1021:	DMRVGVYGAL GLAQGIFVFI AHFWSAFGFV HASNILHKQL LNNILRAPMR FFDTTPTGRI 
1081:	VNRFAGDIST VDDTLPQSLR SWITCFLGII STLVMICMAT PVFTIIVIPL GIIYVSVQMF 
1141:	YVSTSRQLRR LDSVTRSPIY SHFSETVSGL PVIRAFEHQQ RFLKHNEVRI DTNQKCVFSW 
1201:	ITSNRWLAIR LELVGNLTVF FSALMMVIYR DTLSGDTVGF VLSNALNITQ TLNWLVRMTS 
1261:	EIETNIVAVE RITEYTKVEN EAPWVTDKRP PPDWPSKGKI QFNNYQVRYR PELDLVLRGI 
1321:	TCDIGSMEKI GVVGRTGAGK SSLTNCLFRI LEAAGGQIII DGVDIASIGL HDLREKLTII 
1381:	PQDPILFSGS LRMNLDPFNN YSDEEIWKAL ELAHLKSFVA SLQLGLSHEV TEAGGNLSIG 
1441:	QRQLLCLGRA LLRKSKILVL DEATAAVDLE TDNLIQTTIQ NEFAHCTVIT IAHRLHTIMD 
1501:	SDKVMVLDNG KIIECGSPEE LLQIPGPFYF MAKEAGIENV NSTKF